[1]
|
Sung, H., Ferlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
https://doi.org/10.3322/caac.21660
|
[2]
|
Llovet, J.M., Kelley, R.K., Villanueva, A., et al. (2021) Hepatocellular Carcinoma. Nature Reviews Disease Primers, 7, Article No. 6. https://doi.org/10.1038/s41572-020-00240-3
|
[3]
|
Yang, C., Zhang, H., Zhang, L., et al. (2023) Evolving Thera-peutic Landscape of Advanced Hepatocellular Carcinoma. Nature Reviews Gastroenterology & Hepatology, 20, 203-222. https://doi.org/10.1038/s41575-022-00704-9
|
[4]
|
Hybiak, J., Broniarek, I., Kiryczynski, G., et al. (2020) Aspirin and Its Pleiotropic Application. European Journal of Pharmacology, 866, Article ID: 172762. https://doi.org/10.1016/j.ejphar.2019.172762
|
[5]
|
Garcia, R.L., Martin-Perez, M., Hennekens, C.H., Rothwell, P.M. and Lanas, A. (2016) Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies. PLOS ONE, 11, e160046.
https://doi.org/10.1371/journal.pone.0160046
|
[6]
|
Laidlaw, T.M. and Cahill, K.N. (2017) Current Knowledge and Management of Hypersensitivity to Aspirin and NSAIDs. The Journal of Allergy and Clinical Immunology: In Practice, 5, 537-545.
https://doi.org/10.1016/j.jaip.2016.10.021
|
[7]
|
Ren, W., Wang, W. and Guo, Y. (2022) Analysis of Adverse Reac-tions of Aspirin in Prophylaxis Medication Based on FAERS Database. Computational and Mathematical Methods in Medicine, 2022, Article ID: 7882277.
https://doi.org/10.1155/2022/7882277
|
[8]
|
Simon, T.G., Ma, Y., Ludvigsson, J.F., et al. (2018) Association be-tween Aspirin Use and Risk of Hepatocellular Carcinoma. JAMA Oncology, 4, 1683-1690. https://doi.org/10.1001/jamaoncol.2018.4154
|
[9]
|
Devarbhavi, H., Asrani, S.K., Arab, J.P., et al. (2023) Global Burden of Liver Disease: 2023 Update. Journal of Hepatology, 79, 516-537. https://doi.org/10.1016/j.jhep.2023.03.017
|
[10]
|
Lee, T.Y., Hsu, Y.C., Tseng, H.C., et al. (2019) Association of Daily Aspirin Therapy with Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. JAMA Internal Med-icine, 179, 633-640.
https://doi.org/10.1001/jamainternmed.2018.8342
|
[11]
|
Lee, T.Y., Hsu, Y.C., Tseng, H.C., et al. (2020) Association of Daily Aspirin Therapy with Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis C Virus Infection. Clin-ical Gastroenterology and Hepatology, 18, 2784-2792.
https://doi.org/10.1016/j.cgh.2020.04.036
|
[12]
|
Jang, H., Lee, Y.B., Moon, H., et al. (2022) Aspirin Use and Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis B with or without Cirrhosis. Hepatology, 76, 492-501. https://doi.org/10.1002/hep.32380
|
[13]
|
Simon, T.G., Duberg, A.S., Aleman, S., et al. (2020) Association of Aspi-rin with Hepatocellular Carcinoma and Liver-Related Mortality. The New England Journal of Medicine, 382, 1018-1028.
https://doi.org/10.1056/NEJMoa1912035
|
[14]
|
Chang, Y., Jeong, S.W., Jang, J.Y. and Kim, Y.J. (2020) Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. International Journal of Molecular Sciences, 21, Article 8165.
https://doi.org/10.3390/ijms21218165
|
[15]
|
Boas, F.E., Brown, K.T., Ziv, E., et al. (2019) Aspirin Is Associated with Improved Liver Function after Embolization of Hepatocellular Carcinoma. American Journal of Roentgenology, 213, 1-7. https://doi.org/10.2214/AJR.18.20846
|
[16]
|
Li, J.H., Wang, Y., Xie, X.Y., et al. (2016) Aspirin in Combina-tion with TACE in Treatment of Unresectable HCC: A Matched-Pairs Analysis. American Journal of Cancer Research, 6, 2109-2116.
|
[17]
|
Xing, R., Gao, J., Cui, Q. and Wang, Q. (2021) Strategies to Improve the Antitumor Effect of Im-munotherapy for Hepatocellular Carcinoma. Frontiers in Immunology, 12, Article 783236. https://doi.org/10.3389/fimmu.2021.783236
|
[18]
|
Ielasi, L., Tovoli, F., Tonnini, M., et al. (2021) Beneficial Prog-nostic Effects of Aspirin in Patients Receiving Sorafenib for Hepatocellular Carcinoma: A Tale of Multiple Confounders. Cancers, 13, Article 6376.
https://doi.org/10.3390/cancers13246376
|
[19]
|
Casadei-Gardini, A., Rovesti, G., Dadduzio, V., et al. (2021) Impact of Aspirin on Clinical Outcome in Advanced HCC Patients Receiving Sorafenib and Regorafenib. HPB, 23, 915-920. https://doi.org/10.1016/j.hpb.2020.09.024
|
[20]
|
Tan, R.Z.H., Lockart, I., Shaheed, C.A. and Danta, M. (2021) Sys-tematic Review with Meta-Analysis: The Effects of Non-Steroidal Anti-Inflammatory Drugs and Anti-Platelet Therapy on the Incidence and Recurrence of Hepatocellular Carcinoma. Alimentary Pharmacology & Therapeutics, 54, 356-367. https://doi.org/10.1111/apt.16515
|
[21]
|
Li, X., Wu, S. and Yu, Y. (2020) Aspirin Use and the Incidence of Hepato-cellular Carcinoma in Patients with Hepatitis B Virus or Hepatitis C Virus Infection: A Meta-Analysis of Cohort Studies. Frontiers in Medicine, 7, Article 569759.
https://doi.org/10.3389/fmed.2020.569759
|
[22]
|
Pu, D., Yin, L., Huang, L., et al. (2021) Cyclooxygenase-2 Inhibi-tor: A Potential Combination Strategy with Immunotherapy in Cancer. Frontiers in Oncology, 11, Article 637504. https://doi.org/10.3389/fonc.2021.637504
|
[23]
|
Leone, V., Ali, A., Weber, A., et al. (2021) Liver Inflammation and Hepatobiliary Cancers. Trends in Cancer, 7, 606-623. https://doi.org/10.1016/j.trecan.2021.01.012
|
[24]
|
Brighenti, E., Giannone, F.A., Fornari, F., et al. (2016) Therapeutic Dosages of Aspirin Counteract the IL-6 Induced Pro-Tumorigenic Effects by Slowing Down the Ribosome Biogenesis Rate. Oncotarget, 7, 63226-63241.
https://doi.org/10.18632/oncotarget.11441
|
[25]
|
Wang, T., Fu, X., Jin, T., et al. (2019) Aspirin Targets P4HA2 through Inhibiting NF-κB and LMCD1-AS1/let-7g to Inhibit Tumour Growth and Collagen Deposition in Hepatocellular Carcinoma. EBioMedicine, 45, 168-180.
https://doi.org/10.1016/j.ebiom.2019.06.048
|
[26]
|
Cheng, B.Q., Jiang, Y., Zhu, Q. and Li, W.G. (2014) Wnt/β-Catenin Aids in Regulating the Proliferation of hepG2 Cells Mediated by thy-1. Genetics and Molecular Research, 13, 5115-5127. https://doi.org/10.4238/2014.July.7.4
|
[27]
|
Liu, Y.X., Feng, J.Y., Sun, M.M., et al. (2019) Aspirin Inhibits the Proliferation of Hepatoma Cells through Controlling GLUT1-Mediated Glucose Metabolism. Acta Pharma-cologica Sinica, 40, 122-132.
https://doi.org/10.1038/s41401-018-0014-x
|
[28]
|
Yang, G., Wang, Y., Feng, J., et al. (2017) Aspirin Suppresses the Abnormal Lipid Metabolism in Liver Cancer Cells via Disrupting an NFκB-ACSL1 Signaling. Biochemical and Bio-physical Research Communications, 486, 827-832.
https://doi.org/10.1016/j.bbrc.2017.03.139
|
[29]
|
Garcia-Pras, E., Fernandez-Iglesias, A., Gracia-Sancho, J. and Fernández-Iglesias, A. (2021) Cell Death in Hepatocellular Carcinoma: Pathogenesis and Therapeutic Opportunities. Cancers, 14, Article 48.
https://doi.org/10.3390/cancers14010048
|
[30]
|
Yuan, Z., Zhao, J., Wang, Z., et al. (2020) Effects of Aspirin on Hepatocellular Carcinoma and Its Potential Molecular Mechanism. JBUON, 25, 981-986.
|
[31]
|
Hossain, M.A., Kim, D.H., Jang, J.Y., et al. (2012) Aspirin Induces Apoptosis in vitro and Inhibits Tumor Growth of Human Hepatocellular Carcinoma Cells in a Nude Mouse Xenograft Model. International Journal of Oncology, 40, 1298-1304. https://doi.org/10.3892/ijo.2011.1304
|
[32]
|
Huang, Z., Fang, W., Liu, W., et al. (2018) Aspirin Induces Be-clin-1-Dependent Autophagy of Human Hepatocellular Carcinoma Cell. European Journal of Pharmacology, 823, 58-64. https://doi.org/10.1016/j.ejphar.2018.01.031
|
[33]
|
Zhao, Q., Wang, Z., Wang, Z., et al. (2016) Aspirin May Inhibit Angiogenesis and Induce Autophagy by Inhibiting mTOR Signaling Pathway in Murine Hepatocarcinoma and Sarcoma Models. Oncology Letters, 12, 2804-2810.
https://doi.org/10.3892/ol.2016.5017
|
[34]
|
Wong, M.M., Chan, H.Y., Aziz, N.A., et al. (2021) Interplay of Au-tophagy and Cancer Stem Cells in Hepatocellular Carcinoma. Molecular Biology Reports, 48, 3695-3717. https://doi.org/10.1007/s11033-021-06334-9
|
[35]
|
程变巧, 林伟国, 朱琪, 等. 阿司匹林调控Wnt/β-catenin信号通路抑制肝癌侵袭[J]. 临床医药文献电子杂志, 2018, 5(7): 13-15.
|
[36]
|
Sun, D., Liu, H., Dai, X., et al. (2017) Aspirin Disrupts the mTOR-Raptor Complex and Potentiates the Anti-Cancer Activities of Sorafenib via mTORC1 Inhi-bition. Cancer Letters, 406, 105-115.
https://doi.org/10.1016/j.canlet.2017.06.029
|
[37]
|
Xia, H., Lee, K.W., Chen, J., et al. (2017) Simultaneous Silencing of ACSL4 and Induction of GADD45B in Hepatocellular Carcinoma Cells Amplifies the Synergistic Therapeutic Effect of Aspirin and Sorafenib. Cell Death Discovery, 3, Article No. 17058. https://doi.org/10.1038/cddiscovery.2017.58
|
[38]
|
Li, S., Dai, W., Mo, W., et al. (2017) By Inhibiting PFKFB3, Aspirin Overcomes Sorafenib Resistance in Hepatocellular Carcinoma. International Journal of Cancer, 141, 2571-2584. https://doi.org/10.1002/ijc.31022
|
[39]
|
Miao, R., Xu, X., Wang, Z., et al. (2018) Synergistic Effect of Nutlin-3 Combined with Aspirin in Hepatocellular Carcinoma HepG2 Cells through Activation of Bcl-2/Bax Signaling Pathway. Molecular Medicine Reports, 17, 3735-3743. https://doi.org/10.3892/mmr.2017.8346
|
[40]
|
胡亚男, 谷仕艳, 张遵真. 阿司匹林增加人肝癌细胞对三氧化二砷敏感性的实验研究及机制探讨[J]. 四川大学学报(医学版), 2016, 47(2): 159-163.
|
[41]
|
Xie, Z.Y., Liu, M.S., Zhang, C., et al. (2018) Aspirin Enhances the Sensitivity of Hepatocellular Carcinoma Side Population Cells to Doxorubicin via miR-491/ABCG2. Bioscience Reports, 38, BSR20180854.
https://doi.org/10.1042/BSR20180854
|